Biopharma dive · 1d ago
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
Rhyter Times aggregates short excerpts. The full story is reported by Biopharma dive.
Read the full story at Biopharma dive →